Infant Immunity after Maternal Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn
{{output}}
Background: Antenatal treatment with nipocalimab, a neonatal Fc receptor (FcRn) blocker, delayed or prevented fetal anemia, as compared with a historical benchmark, in a phase 2 study of early-onset severe hemolytic disease of th... ...
